146 related articles for article (PubMed ID: 8439507)
21. Noninvasive squamous lesions in the urinary bladder: a clinicopathologic analysis of 29 cases.
Guo CC; Fine SW; Epstein JI
Am J Surg Pathol; 2006 Jul; 30(7):883-91. PubMed ID: 16819332
[TBL] [Abstract][Full Text] [Related]
22. p53 mutation and bcl-2 expression in transitional cell carcinoma of the urinary bladder.
Wu TT; Lee YH; Huang JK
Zhonghua Yi Xue Za Zhi (Taipei); 2001 Jan; 64(1):9-14. PubMed ID: 11310375
[TBL] [Abstract][Full Text] [Related]
23. Immunocytochemical localization of c-erbB-2 protein in transitional cell carcinoma of the urinary bladder.
Coombs LM; Oliver S; Sweeney E; Knowles M
J Pathol; 1993 Jan; 169(1):35-42. PubMed ID: 8094432
[TBL] [Abstract][Full Text] [Related]
24. Molecular and immunohistochemical evaluation of epidermal growth factor receptor and c-erb-B-2 gene product in transitional cell carcinomas of the urinary bladder: a study in Greek patients.
Gorgoulis VG; Barbatis C; Poulias I; Karameris AM
Mod Pathol; 1995 Sep; 8(7):758-64. PubMed ID: 8539234
[TBL] [Abstract][Full Text] [Related]
25. Transurethral bladder tumor resection alters fibronectin expression in transitional carcinoma cell lines.
See WA; Xu Y; Gee K; Severson C; Cohen MB; Ladehoff D
J Urol; 1997 Mar; 157(3):1136-43. PubMed ID: 9072558
[TBL] [Abstract][Full Text] [Related]
26. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression.
Sarkis AS; Dalbagni G; Cordon-Cardo C; Zhang ZF; Sheinfeld J; Fair WR; Herr HW; Reuter VE
J Natl Cancer Inst; 1993 Jan; 85(1):53-9. PubMed ID: 7677935
[TBL] [Abstract][Full Text] [Related]
27. The loss of expression of transforming growth factor-beta receptors correlates with the histopathologic tumor grade in bladder transitional cell carcinoma patients.
Lee DH; Yang SC; Hong SJ; Chung BH; Chung HJ; Tokunaga H; Kim IY; Song YS; Lerner SP; Morton RA
Yonsei Med J; 1999 Apr; 40(2):118-23. PubMed ID: 10333714
[TBL] [Abstract][Full Text] [Related]
28. Detection of residual tumor cells in bladder biopsy specimens: pitfalls in the interpretation of cytokeratin stains.
Tamas EF; Epstein JI
Am J Surg Pathol; 2007 Mar; 31(3):390-7. PubMed ID: 17325480
[TBL] [Abstract][Full Text] [Related]
29. Transient receptor potential vanilloid type 2 (TRPV2) expression in normal urothelium and in urothelial carcinoma of human bladder: correlation with the pathologic stage.
Caprodossi S; Lucciarini R; Amantini C; Nabissi M; Canesin G; Ballarini P; Di Spilimbergo A; Cardarelli MA; Servi L; Mammana G; Santoni G
Eur Urol; 2008 Sep; 54(3):612-20. PubMed ID: 17977643
[TBL] [Abstract][Full Text] [Related]
30. Expression of CD147, BIGH3 and Stathmin and their potential role as diagnostic marker in patients with urothelial carcinoma of the bladder.
Bhagirath D; Abrol N; Khan R; Sharma M; Seth A; Sharma A
Clin Chim Acta; 2012 Oct; 413(19-20):1641-6. PubMed ID: 22626996
[TBL] [Abstract][Full Text] [Related]
31. DNA, RNA and immunohistochemical characterization of the HER-2/neu oncogene in transitional cell carcinoma of the bladder.
Wood DP; Wartinger DD; Reuter V; Cordon-Cardo C; Fair WR; Chaganti RS
J Urol; 1991 Nov; 146(5):1398-401. PubMed ID: 1942310
[TBL] [Abstract][Full Text] [Related]
32. Effect of epidermal growth factor/transforming growth factor alpha and transforming growth factor beta 1 on growth in vitro of rat urinary bladder carcinoma cells.
Kawamata H; Azuma M; Kameyama S; Nan L; Oyasu R
Cell Growth Differ; 1992 Nov; 3(11):819-25. PubMed ID: 1467309
[TBL] [Abstract][Full Text] [Related]
33. Altered mRNA expression of the Rb and p16 tumor suppressor genes and of CDK4 in transitional cell carcinomas of the urinary bladder associated with tumor progression.
Quentin T; Henke C; Korabiowska M; Schlott T; Zimmerman B; Kunze E
Anticancer Res; 2004; 24(2B):1011-23. PubMed ID: 15161057
[TBL] [Abstract][Full Text] [Related]
34. Expression patterns of the immune checkpoint ligand CD276 in urothelial carcinoma.
Aicher WK; Korn M; Reitnauer L; Maurer FB; Hennenlotter J; Black PC; Todenhofer T; Bedke J; Stenzl A
BMC Urol; 2021 Apr; 21(1):60. PubMed ID: 33845814
[TBL] [Abstract][Full Text] [Related]
35. Expression of bcl-2 and bcl-X in bladder cancer.
Kirsh EJ; Baunoch DA; Stadler WM
J Urol; 1998 Apr; 159(4):1348-53. PubMed ID: 9507882
[TBL] [Abstract][Full Text] [Related]
36. Urinary bladder transitional cell carcinogenesis is associated with down-regulation of NF1 tumor suppressor gene in vivo and in vitro.
Aaltonen V; Boström PJ; Söderström KO; Hirvonen O; Tuukkanen J; Nurmi M; Laato M; Peltonen J
Am J Pathol; 1999 Mar; 154(3):755-65. PubMed ID: 10079253
[TBL] [Abstract][Full Text] [Related]
37. DNA content and proliferation activity in superficial transitional cell carcinoma of the bladder.
Pantazopoulos D; Ioakim-Liossi A; Karakitsos P; Aroni K; Kakoliris S; Kanavaros P; Kyrkou KA
Anticancer Res; 1997; 17(1B):781-6. PubMed ID: 9066620
[TBL] [Abstract][Full Text] [Related]
38. [Urothelial hyperplastic lesion with endophytic growth pattern: a clinicopathologic study].
Xiao L; Wang CF; Zhu XZ; Yin YL; Chen Y; Lu C; Yu B
Zhonghua Bing Li Xue Za Zhi; 2011 May; 40(5):319-23. PubMed ID: 21756826
[TBL] [Abstract][Full Text] [Related]
39. Alteration of the vascular endothelial growth factor and angiopoietins-1 and -2 pathways in transitional cell carcinomas of the urinary bladder associated with tumor progression.
Quentin T; Schlott T; Korabiowska M; Käthei N; Zöller G; Glaser F; Kunze E
Anticancer Res; 2004; 24(5A):2745-56. PubMed ID: 15517881
[TBL] [Abstract][Full Text] [Related]
40. Expression of p53 in urothelial cell cultures from tumour-bearing and tumour-free patients.
Harney J; Murphy DM; Jones M; Mothersill C
Br J Cancer; 1995 Jan; 71(1):25-9. PubMed ID: 7819043
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]